Bioactive molecules produced by the co-cultivation of microbes have the potential to be used as antibiotics. A method for the production and purification of new bioactive molecules would open the door to potentially unlimited varieties of antibiotics.
Microbiologists have long worried about the growing resistance of bacteria and other microbes to existing antibacterial agents due to the overuse of antibiotics. As a result, there is an on-going need to develop new antibiotics to counteract this evolution of resistance.
This invention involves the co-incubation of Rhodococcus fascians with Streptomyces padanus to produce two new isomeric antibiotics, coined rhodostreptomycin A and B. The Rhodococcus fascians strain that developed the ability to produce these two new antibiotics, 307CO, was able to eliminate Streptomyces from its culture, presumably by the toxicity of rhodostreptomycin A and B. The inventors have hypothesized that Rhodococcus fascians gained the ability to produce rhodostreptomycin through a lateral gene transfer from its co-cultured Streptomyces. Genomic analysis revealed that 307CO harbored a long strand of DNA derived from Streptomyces. Furthermore, rhodostreptomycin A and B production correlated with the presence of Streptomyces-derived DNA in Rhodococcus. Rhodostreptomycin was purified by fractionation, cation exchange, and reverse-phased HLPC. NMR analysis was used to reveal the chemical formula and hydrocarbon structure of rhodostreptomycin A and B and verify their novelty. Rhodostreptomycin A and B were not shown to have any activity against eukaryotes when applied to S. Cerevisiae or human leukemia (HL-60).
Method for the production of new antibiotics
Production of two new antibiotics, rhodostreptomycin A and B, by bacterial strain Rhodococcus fascians 307CO
Eukaryotes unaffected by rhodostreptomycin A and B